Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study
Wall Street Journal
Merck & Co. is ending a late-stage study of the combination of Keytruda and Lynparza in certain lung cancer patients due to an expected failure of the trial.
https://www.wsj.com/articles/merck-scraps-phase-3-keytruda-lynparza-lung-cancer-study-ecad6bb4